Qurient and Lonza Take Dual-Payload ADC Platform to Global Meetings

Qurient and Lonza are promoting their jointly developed dual-payload antibody-drug conjugate platform, SYN-duo CC, at international industry meetings. The presentations put the technology before potential partners, but they do not establish that it has secured customers or demonstrated clinical benefits.

From San Diego to London

Lonza introduced SYN-duo CC at World ADC in San Diego, and the platform was subsequently presented at an ELRIG drug discovery conference in London. The appearances extend its exposure beyond a single event as the companies pursue global commercialization.

A dual-payload ADC is designed to carry two drug components on an antibody. That design may give developers more options in constructing a treatment, but its value will depend on evidence from specific drug candidates. The conference presentations alone do not show how the platform performs in patients.

The commercial question

For Qurient, the next measure of progress is whether interest in the platform turns into development work or commercial agreements. The company’s regulatory filing provides financial context: revenue changed +3.42% (Q2 2025 → Q2 2026), while its operating margin was −672.86% (Q2 2026). Those figures describe the filed periods; they do not measure the outcome of the Lonza collaboration.

By the Numbers